hims glp-1 side effects Inc Hims & Hers tackles high

Particularly, the ability to reduce weight has increased their use among patients who are obese but do not have diabetes

The STEP 1 trial for semaglutide 2.4mg demonstrated a mean body weight reduction of approximately 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial for tirzepatide showed reductions of up to 22.5% at the highest dose. These are outcomes that approach the efficacy of bariatric surgery in some patient cohorts

Supports Steady, Meaningful Weight Loss Patients in clinical trials achieved significant weight loss over time, particularly when treatment is combined with healthy eating, physical activity, and behavioural support

Vitamins bypass your gut entirely , delivering a more effective dose

Retrieved August 21, 2025, from Prime Therapeutics

Compounded versions sometimes come in different delivery formats as well